ClinicalTrials.gg
Drug

Everolimus clinical trials

Also written RAD001, Afinitor and Certican.

studies test it
616
open now
41
in phase 3
84
first study started
2000
Related medicines add 2 studies

Counted the way a researcher would: Everolimus with its salts, dosage forms, brands and biosimilars. Looking for a trial to join? Including related medicines shows more you could take part in.

This browser remembers your choice.

How each study uses Everolimus is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the Everolimus studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
30 Mar 2009 · AFINITOR · NDA 022334 (FDA, Drugs@FDA)
European Union
2 Aug 2009 · Afinitor · EMEA/H/C/001038 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Everolimus
457
42-O-(2-Hydroxy)ethyl Rapamycin
37
Everolimus (RAD001)
21
RAD001 (Everolimus)
9
RAD001, Afinitor ®
4

Brand

Afinitor
134
Certican
77
Zortress
61
Votubia
28

Development codes

RAD001
230
NSC-733504
1

In one entry with another drug

Given together, or one or the other

Everolimus and tacrolimus
2

Studies by the year they started

614 studies that test it; most in 2009 (70)

Studies that test Everolimus, by start year
YearStudies
20001
20012
20021
20032
200414
200527
200633
200731
200857
200970
201066
201150
201251
201336
201438
201524
201621
201718
20187
20199
20206
20215
20227
20238
202412
20257
202611

By phase

A phase 1/2 study counts in both.

Early Phase 1
9
Phase 1
173
Phase 2
326
Phase 3
84
Phase 4
81
No phase
21

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 130 · Other 486

Novartis Pharmaceuticals (112) · M.D. Anderson Cancer Center (30) · Dana-Farber Cancer Institute (15) · Memorial Sloan Kettering Cancer Center (14) · Emory University (11) · Fudan University (9) · Mayo Clinic (9) · SCRI Development Innovations, LLC (9)

Often tested with

Tested in the same studies.

Tacrolimus (18) · Letrozole (13) · Sorafenib (13) · Bevacizumab (13) · Mycophenolic Acid (12) · Pazopanib (9) · Paclitaxel (9) · Capecitabine (9)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Tested against it · 9 phase 3 studies under way

Everolimus is the comparator. A study of two new drugs counts under both.

  • 2177Lu-octreotide, DOTA(0)-Tyr(3)- · ITM Solucin GmbH, Grupo Espanol de Tumores Neuroendocrinos · next primary completion Mar 2029
  • 1Belzutifan · Merck Sharp & Dohme LLC
  • 1Actinium AC-225 dotatate · RayzeBio, Inc. · next primary completion Dec 2026
  • 1Zanzalintinib · Exelixis · next primary completion Jun 2029
  • 1Dordaviprone · Gustave Roussy, Cancer Campus, Grand Paris · next primary completion Sep 2028
  • 1HRS-8080 · Shandong Suncadia Medicine Co., Ltd. · next primary completion Aug 2027
  • 1Sirolimus · CSPC ZhongQi Pharmaceutical Technology Co., Ltd. · next primary completion Aug 2028
Reaching primary completion within a year · 16, 3 in phase 3

Studies that test Everolimus, phase 3 first.

Studies

Open first, then newest update. How each study uses Everolimus is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 616

See all 616 studies that test Everolimus →

Given beside what is tested · 105 — Everolimus is usual care or a partner of the new treatment

Showing 20 of 105.

As the comparator · 30 — what is tested is compared with Everolimus

Showing 20 of 30.

What changed recently

From the registry's own updates since Oct 18, 2026.

Codes

What other systems call Everolimus · ClinicalTrials.gg INT006510

  • MeSH (NLM) D000068338EverolimusConfirmed ClinicalTrials.gov, NLM, Wikidata
  • UNII (FDA) 9HW64Q8G6GEVEROLIMUSConfirmed FDA, NLM, Wikidata
  • RxNorm 141704Confirmed FDA, Wikidata
  • Wikidata Q421052everolimusConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C48387EverolimusOne source FDA
  • DrugBank DB01590One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.